Gefitinib
Sign in to save this workspacePrimary targets: EGFR · FDA status: FDA Approved
Selectivity scorecard
KISS
99.25
Gini
0.650
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Gefitinib. Strongest target: EGFR at 99.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 99.9% | 0.1% |
| 2 | ERBB4_HER4 | 96.8% | 3.2% |
| 3 | ERBB2_HER2 | 92.2% | 7.8% |
| 4 | DDR1 | 88.3% | 11.7% |
| 5 | LYN | 80.1% | 19.9% |
| 6 | LOK_STK10 | 79.2% | 20.8% |
| 7 | EPHA6 | 77.4% | 22.6% |
| 8 | LCK | 71.4% | 28.6% |
| 9 | RIPK3 | 71.4% | 28.6% |
| 10 | MNK1 | 68.7% | 31.3% |
| 11 | FLT3 | 62.7% | 37.3% |
| 12 | IRAK1 | 62.4% | 37.6% |
| 13 | SIK2 | 61.4% | 38.6% |
| 14 | SIK1 | 57.7% | 42.3% |
| 15 | RIPK2 | 57.5% | 42.5% |
| 16 | MNK2 | 54.3% | 45.7% |
| 17 | HIPK4 | 50.4% | 49.6% |
| 18 | BLK | 49.4% | 50.6% |
| 19 | MEK5 | 48.5% | 51.5% |
| 20 | P38A_MAPK14 | 47.5% | 52.5% |
Selectivity landscape
Where Gefitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Gefitinib.
Annotations
Sign in to read and post annotations.
Loading…